514 related articles for article (PubMed ID: 12560194)
1. Post-kala-azar dermal leishmaniasis.
Zijlstra EE; Musa AM; Khalil EA; el-Hassan IM; el-Hassan AM
Lancet Infect Dis; 2003 Feb; 3(2):87-98. PubMed ID: 12560194
[TBL] [Abstract][Full Text] [Related]
2. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S59-76. PubMed ID: 11370251
[TBL] [Abstract][Full Text] [Related]
3. Leishmaniasis in Sudan. Visceral leishmaniasis.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S27-58. PubMed ID: 11370250
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis--an overview.
Ganguly S; Das NK; Barbhuiya JN; Chatterjee M
Int J Dermatol; 2010 Aug; 49(8):921-31. PubMed ID: 21128917
[TBL] [Abstract][Full Text] [Related]
5. Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.
Ramesh V; Kaushal H; Mishra AK; Singh R; Salotra P
BMC Public Health; 2015 Oct; 15():1092. PubMed ID: 26503551
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
7. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.
Marlais T; Bhattacharyya T; Singh OP; Mertens P; Gilleman Q; Thunissen C; Hinckel BCB; Pearson C; Gardner BL; Airs S; de la Roche M; Hayes K; Hafezi H; Falconar AK; Eisa O; Saad A; Khanal B; Bhattarai NR; Rijal S; Boelaert M; El-Safi S; Sundar S; Miles MA
Front Cell Infect Microbiol; 2018; 8():427. PubMed ID: 30619774
[No Abstract] [Full Text] [Related]
8. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
10. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
11. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
Zijlstra EE
Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
[TBL] [Abstract][Full Text] [Related]
12. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
14. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan.
Khalil EA; Zijlstra EE; Kager PA; El Hassan AM
Trop Med Int Health; 2002 Jan; 7(1):35-44. PubMed ID: 11851953
[TBL] [Abstract][Full Text] [Related]
16. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM; Ismael A
Am J Trop Med Hyg; 1995 Apr; 52(4):299-305. PubMed ID: 7741164
[TBL] [Abstract][Full Text] [Related]
17. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.
Saha S; Mazumdar T; Anam K; Ravindran R; Bairagi B; Saha B; Goswami R; Pramanik N; Guha SK; Kar S; Banerjee D; Ali N
J Clin Microbiol; 2005 Mar; 43(3):1269-77. PubMed ID: 15750095
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in post-kala-azar dermal leishmaniasis.
Mondal D; Khan MG
Curr Opin Infect Dis; 2011 Oct; 24(5):418-22. PubMed ID: 21885919
[TBL] [Abstract][Full Text] [Related]
19. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
[TBL] [Abstract][Full Text] [Related]
20. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
